DNMT inhibitors (DNMTis) like azacitidine and decitabine reactivate these genes and enhance tumor antigen presentation by boosting the expression of tumor-associated antigens (TAA) and cytokines such as IL-2 and IFN-γ. Here, DNMT1 is linked to neoplasm.